Orega Biotech

Latest news and report

21 June 2024
CICON 2024
Read more
26 June 2023
First patient dosed in phase 2 MATISSE trial of IPH5201
Read more
10 April 2023
AACR annual meeting 2023
Read more
24 February 2023
IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE
Read more
23 December 2022
Happy holidays and Merry Christmas !
Read more
6 December 2022
OREGA enters into a License Agreement with Genmab
Read more
20 October 2022
37th SITC annual meeting 2022
Read more
3 June 2022
PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2
Read more